source
- ProMIS Neurosciences early trial shows low brain bleeding and no swelling, hinting at safer Alzheimer’s drugProMIS Neurosciences reported interim safety data from a early‑stage trial of its amyloid‑targeting therapy for Alzheimer’s disease. The analysis pooled data from participants receiving the investi…
- GSK launches three-year £1.9bn savings plan to boost late-stage R&D and relocate research HQGSK announced a three-year cost-saving programme designed to free cash for its late-stage research and development pipeline while moving its research headquarters. The plan targets annual savings…